The EMBARK Trial: Enzalutamide Plus ADT Achieves Unprecedented OS in nmCSPC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

High-Risk Prostate Cancer Survival Improved 40% with Drug Combo

A Phase III clinical trial led by Cedars-Sinai Cancer researchers has shown that a combination therapy of enzalutamide with standard hormone therapy reduced the risk of death by 40% in patients with high-risk biochemically recurrent prostate cancer. Results of the EMBARK trial, published in The New England Journal of Medicine, could change treatment approaches for this subset of prostate cancer patients whose options are limited after surgery or…

The EMBARK Trial: Enzalutamide Plus ADT Achieves Unprecedented OS in nmCSPC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

EMBARK data indicate large OS benefit with enzalutamide/ADT in prostate cancer

Stephen J. Freedland, MD, reported that with combination enzalutamide/leuprolide, the risk of death was 40.3% lower vs leuprolide alone.